Antoxerene Raises $1.5m to Fuel Small Molecule Drug Discovery

Antoxerene, Inc. logo


We are happy to share that our client, Antoxerene, Inc., just received a $1.5 million investment to further develop technology that will help identify potential new pharmaceuticals for cancer and cellular-aging treatments.

One of our specialties at Newman & Lickstein, LLP is helping life science & biotechnology professionals navigate through the pivotal moments of their corporate lifecycle to achieve their most critical business and legal goals.

Read more at:

Related Attorneys

Related Practice Areas / Industries